Endometrial mixed adenocarcinoma
MONDO:0004321An adenocarcinoma that arises from the endometrium and is characterized by the presence of both type I and type II endometrial adenocarcinoma components. The minor component constitutes at least 5% of the entire tumor.
Also known as: endometrial mixed adenocarcinoma
2866 clinical trials for this condition and its sub-types, 10 tagged with Endometrial mixed adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Targeted therapy boost for aggressive uterine cancer under study
Disease control Recruiting nowThis phase 3 trial tests whether adding targeted drugs (trastuzumab and pertuzumab) to standard chemotherapy can better shrink tumors in people with HER2-positive endometrial cancer. The study plans to enroll 360 participants with various stages of the disease. However, the trial…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
Immunotherapy duo shows promise for Tough-to-Treat uterine cancer
Disease control Recruiting nowThis phase II trial is testing whether combining two immunotherapy drugs, nivolumab and ipilimumab, works better than nivolumab alone for women with recurrent endometrial cancer that has a specific DNA repair defect (dMMR). About 81 participants will receive either the combinatio…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
New hope for Obesity-Linked endometrial cancer: experimental combo enters human trials
Disease control Recruiting nowThis early-stage trial tests the safety of combining two drugs, ONC201 and atezolizumab, in 58 women with advanced or recurrent endometrial cancer. The study includes both obese and non-obese participants to see if body weight affects treatment. The goal is to find the best dose …
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC